Kezar Life Sciences, Inc. (KZR)
May 11, 2026 - KZR was delisted (reason: acquired by AUPH)
7.29
0.00 (0.00%)
Inactive · Last trade price on May 8, 2026
Kezar Life Sciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
53.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 7.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKZR News
- 21 days ago - Kezar Life Sciences Quarterly report: Q1 2026 - Filings
- 2 months ago - Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Business Wire
- 2 months ago - Kezar Life Sciences Annual report: Q4 2025 - Filings
- 2 months ago - Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences - Business Wire
- 5 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - Business Wire
- 7 months ago - Kezar Life Sciences Reports Third Quarter 2025 Financial Results - Business Wire
- 7 months ago - Kezar Life Sciences Earnings release: Q3 2025 - Filings
- 7 months ago - Kezar Life Sciences Quarterly report: Q3 2025 - Filings